(VIANEWS) – The NASDAQ ended the session with Catalyst Pharmaceuticals (CPRX) jumping 9.62% to $15.96 on Thursday while NASDAQ rose 0.9% to $16,091.92.
Catalyst Pharmaceuticals’s last close was $14.56, 20.09% below its 52-week high of $18.22.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Earnings Per Share
As for profitability, Catalyst Pharmaceuticals has a trailing twelve months EPS of $0.55.
PE Ratio
Catalyst Pharmaceuticals has a trailing twelve months price to earnings ratio of 29.02. Meaning, the purchaser of the share is investing $29.02 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.06%.
Sales Growth
Catalyst Pharmaceuticals’s sales growth is 74.7% for the ongoing quarter and 22.9% for the next.
More news about Catalyst Pharmaceuticals (CPRX).
